New Directions in Acute Myeloid Leukemia
Presented by Kelda Gardner, PA-C, MHS, and Melinda Tran, PharmD, BCOP
University of Washington, Seattle, Washington; and YouScript, Inc., and the University of Washington, Seattle, Washington
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2019;10(3):299–303 |
© 2019 Harborside™
Acute myeloid leukemia (AML) is diagnosed in about 20,000 people a year and remains a very challenging malignancy to treat. Kelda Gardner, PA-C, MHS, and Melinda Tran, PharmD, BCOP, reviewed the basics of treating AML, including new assessment approaches, treating hematologic emergencies, and the safety and efficacy of novel agents.
For access to the full length article, please sign in